Weight-loss drug Belviq may increase cancer risk, FDA says

doctor's office
Posted at 6:03 AM, Jan 15, 2020
and last updated 2020-01-15 07:33:33-05

On Tuesday, the U.S. Food and Drug Administration announced that a weigh-loss drug may increase your risk of cancer.

The FDA says a clinical trial assessing safety revealed a possible increased risk with the drug Belviq, Belviq XR (lorcaserin).

NATIONAL NEWS | The latest headlines from across the country

"At this time, the cause of the cancer is uncertain, and we cannot conclude that lorcaserin contributes to the cancer risk. However, we wanted to make the public aware of this potential risk," the FDA said. "We are continuing to evaluate the clinical trial results and will communicate our final conclusions and recommendations when we have completed our review."

The trial was conducted over 5 years with approximately 12,000 participants. The FDA says more patients taking lorcaserin in the trial were diagnosed with cancer compared to patients taking placebo pills.

The FDA says the evaluation of the results is on-going. For more information click here.